

Journal of Hepatology CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
pJak1(Tyr1034/1035)		Cell Signaling Technology	74129	
Jak1		Cell Signaling Technology	50996	
pJak2 (Tyr1007/1008)		Cell Signaling Technology	3776	
Jak2		Cell Signaling Technology	3230	
pSTAT3 (Tyr705)		Cell Signaling Technology	9131	
STAT3		Cell Signaling Technology	9139	
pSTAT1 (Tyr701)		Cell Signaling Technology	9167	
STAT1		Cell Signaling Technology	9176	
β-actin		Sigma-Aldrich	A2228	
Factor VIII		Novus Biologicals	NB100-91761	
vWF		Dako	A0082	
Fibrinogen		Dako	A0080	
CD61		Dako	M0753	
CD41		Bio Rad	MCA2245	
Integrin alpha IIb		Santa Cruz Biotechnology	sc365938	
IRDye Donkey anti-Rabbit 680RD		LI-COR	925-68073	
IRDye Donkey anti-Mouset 800CW		LI-COR	926-32212	
Donkey anti-rabbit Alexa 647		Invitrogen	A31573	
Donkey anti-rat Alexa 488		Invitrogen	A21208	
Alexa Fluor 488 phalloidin		moleculer probee	A1239	

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
N/A					

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
N/A						

1.4 Sequence based reagents

Human Gene Name	Primer Sequences (5'-3')	Supplier
Factor VIII	F: GTGCCTTTTGCATTCTGCT R: GCAGCTCACCGAGATCACTT	Yale
vWF	F: CCATCGAGGTGAAGCACAGT R: CCATGTTCCACCCACGTAA	Yale
IL-6	F: ACCCCCAGGAGAAGATTCCA R: GATGCCGTCGAGGATGTACC	Yale
CXCL1	F: GCGCCCAAACCGAAGTCATA R: ATGGGGGATGCAGGATTGAG	Yale
CXCL2	F: GGCAGAAAGCTTGTCTCAACCC R: CTCCTTCAGGAACAGCCACCAA	Yale
ICAM1	F: AGGATGGCACTTTCCCACTG R: GGAGAGCACATTACGGTCA	Yale
VCAM1	F: GTCTCATTGACTTGCAGCACC R: AGATGTGGTCCCCTCATTCTG	Yale
P-selectin	F: ATTGTACTIONCGATCGGGACGC R: AGAGAAATGGCAGGTGGAGC	Yale
E-selectin	F: AAGGCTTCATGTTGCAGGGA R: ATTCATGTAGCCTCGCTCGG	Yale
18S	F: GGCCCTGTAATTGGAATGAGTC R: CCAAGATCCAACACTACGAGCTT	Yale
Mouse Gene name	Primer Sequences (5'-3')	Supplier
IL-6	F: ACAAGTCGGAGGCTTAATTACACAT R: TTGCCATTGCACAACCTCTTTTC	Yale
Fibrinogen α	F: GCCCAACGAGAGACTGTGAT R: CCATCCTCCCAAACCTGGTCTC	Yale
18S	F: ACGGAAGGGCACCACCAGGA R: CACCACCACCCACGGAATCG	Yale

1.5 Biological samples

Description	Source	Identifier
N/A		

1.6 Deposited data

Name of repository	Identifier	Link
N/A		

1.7 Software

Software name	Manufacturer	Version
Image J	NIH	1.53C
Prism	Prism	7.0a
JMP	SAS Institute	15
FlowJo	FlowJo LLC	10.7.1

--	--	--

1.8 Other (e.g. drugs, proteins, vectors etc.)

STAT1 siRNA	M-003543-01-005	Dharmacon
STAT3 siRNA	M-003544-02-005	Dharmacon
Recombinant human IL6	206-IL	R&D systems
Recombinant soluble IL6R α	227-SR	R&D systems
Recombinant soluble gp130	228-GP	R&D systems
Ruxolitinib (phosphate)	23215	Cayman CHEMICAL
Filgotinib	17669	Cayman CHEMICAL
DAPI	F6057	Sigma-Aldrich
ScreenFect TM A	299-73203	Wako Chemicals USA

1.9 Please provide the details of the corresponding methods author for the manuscript:

Prepared by Nao Kawaguchi (nao.kawaguchi@yale.edu) & Yasuko Iwakiri (yasuko.iwakiri@yale.edu)
Department of Internal Medicine
Section of Digestive Diseases
Yale School of Medicine
New Haven, CT 06520
Phone: 203-785-6204

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

N/A